Artificial tears (Hypromellose)
FDA Approved
Description
Artificial tears containing hypromellose provide lubrication and moisture to the ocular surface. They are used in the management of corneal dystrophies including Meesmann corneal dystrophy to alleviate symptoms of dry eye, irritation, and discomfort. Regular application helps maintain corneal hydration and reduce epithelial friction.
Indications & Therapeutic Use
Dry eye syndrome, corneal dystrophies, ocular surface irritation
Linked Diseases:
Meesmann corneal dystrophy
D053559
Global Availability (9 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — |
Available Through
This drug is available for procurement through the following fulfilment partner.
Fulfilment Partner
Artificial tears (Hypromellose)
| Generic Name | Artificial tears (Hypromellose) |
| Brands | 1 brand available |
| Active Ingredient | Hypromellose |
| Drug Class | Dry eye syndrome |
| Manufacturer | Alcon |
| Dosage Forms | Ophthalmic solution 0.3%, 0.5% |
| Medical Code | S01XA20 |
| Orphan Status | No |
| Cold Chain | Not Required |
| Lead Time | 1 days |
| Reg. Status | FDA Approved |
| Countries | 9 countries |
Authority Signals
Last Verified3/21/2026
Data ConfidenceHigh (AI + Pharmacist)
Source Citations10 Validated Nodes